vs
MetroCity Bankshares, Inc.（MCBS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
MetroCity Bankshares, Inc.的季度营收约是REGENXBIO Inc.的1.4倍（$43.7M vs $30.3M），MetroCity Bankshares, Inc.净利率更高（50.5% vs -221.3%，领先271.8%），REGENXBIO Inc.同比增速更快（43.0% vs 23.6%），MetroCity Bankshares, Inc.自由现金流更多（$37.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 15.7%）
MetroCity Bankshares, Inc.旗下的大都会城市银行是一家韩裔美国人创办的银行，总部位于佐治亚州多拉维尔，提供个人及商业银行服务。它是总部不在加利福尼亚州洛杉矶的最大韩美系银行，目前在德克萨斯、纽约、新泽西、弗吉尼亚、佐治亚、阿拉巴马和佛罗里达共设有19家分行。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
MCBS vs RGNX — 直观对比
营收规模更大
MCBS
是对方的1.4倍
$30.3M
营收增速更快
RGNX
高出19.4%
23.6%
净利率更高
MCBS
高出271.8%
-221.3%
自由现金流更多
MCBS
多$89.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
15.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $43.7M | $30.3M |
| 净利润 | $18.1M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 52.8% | -190.0% |
| 净利率 | 50.5% | -221.3% |
| 营收同比 | 23.6% | 43.0% |
| 净利润同比 | 11.7% | -31.2% |
| 每股收益（稀释后） | $0.69 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MCBSRGNX
| Q4 25 | $43.7M | $30.3M | ||
| Q3 25 | $38.0M | $29.7M | ||
| Q2 25 | $37.9M | $21.4M | ||
| Q1 25 | $36.0M | $89.0M | ||
| Q4 24 | $35.4M | $21.2M | ||
| Q3 24 | $36.9M | $24.2M | ||
| Q2 24 | $36.3M | $22.3M | ||
| Q1 24 | $32.7M | $15.6M |
净利润MCBSRGNX
| Q4 25 | $18.1M | $-67.1M | ||
| Q3 25 | $17.3M | $-61.9M | ||
| Q2 25 | $16.8M | $-70.9M | ||
| Q1 25 | $16.3M | $6.1M | ||
| Q4 24 | $16.2M | $-51.2M | ||
| Q3 24 | $16.7M | $-59.6M | ||
| Q2 24 | $16.9M | $-53.0M | ||
| Q1 24 | $14.6M | $-63.3M |
毛利率MCBSRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率MCBSRGNX
| Q4 25 | 52.8% | -190.0% | ||
| Q3 25 | 62.8% | -176.3% | ||
| Q2 25 | 62.4% | -296.3% | ||
| Q1 25 | 61.3% | 13.6% | ||
| Q4 24 | 58.9% | -242.1% | ||
| Q3 24 | 61.4% | -256.6% | ||
| Q2 24 | 64.4% | -251.3% | ||
| Q1 24 | 62.6% | -408.8% |
净利率MCBSRGNX
| Q4 25 | 50.5% | -221.3% | ||
| Q3 25 | 45.5% | -208.3% | ||
| Q2 25 | 44.4% | -331.8% | ||
| Q1 25 | 45.3% | 6.8% | ||
| Q4 24 | 54.0% | -241.3% | ||
| Q3 24 | 45.3% | -246.3% | ||
| Q2 24 | 46.7% | -237.7% | ||
| Q1 24 | 44.8% | -405.4% |
每股收益（稀释后）MCBSRGNX
| Q4 25 | $0.69 | $-1.30 | ||
| Q3 25 | $0.67 | $-1.20 | ||
| Q2 25 | $0.65 | $-1.38 | ||
| Q1 25 | $0.63 | $0.12 | ||
| Q4 24 | $0.64 | $-0.99 | ||
| Q3 24 | $0.65 | $-1.17 | ||
| Q2 24 | $0.66 | $-1.05 | ||
| Q1 24 | $0.57 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.7M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $544.2M | $102.7M |
| 总资产 | $4.8B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MCBSRGNX
| Q4 25 | $383.7M | $230.1M | ||
| Q3 25 | $227.2M | $274.2M | ||
| Q2 25 | $286.0M | $323.3M | ||
| Q1 25 | $285.1M | $267.9M | ||
| Q4 24 | $249.9M | $234.7M | ||
| Q3 24 | $291.2M | $255.5M | ||
| Q2 24 | $327.9M | $290.4M | ||
| Q1 24 | $258.8M | $338.7M |
股东权益MCBSRGNX
| Q4 25 | $544.2M | $102.7M | ||
| Q3 25 | $445.9M | $161.5M | ||
| Q2 25 | $436.1M | $213.7M | ||
| Q1 25 | $428.0M | $274.2M | ||
| Q4 24 | $421.4M | $259.7M | ||
| Q3 24 | $407.2M | $301.4M | ||
| Q2 24 | $407.2M | $348.3M | ||
| Q1 24 | $396.6M | $390.7M |
总资产MCBSRGNX
| Q4 25 | $4.8B | $453.0M | ||
| Q3 25 | $3.6B | $525.2M | ||
| Q2 25 | $3.6B | $581.0M | ||
| Q1 25 | $3.7B | $490.9M | ||
| Q4 24 | $3.6B | $466.0M | ||
| Q3 24 | $3.6B | $519.1M | ||
| Q2 24 | $3.6B | $569.4M | ||
| Q1 24 | $3.6B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $37.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $37.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | 84.7% | -174.0% |
| 资本支出强度资本支出/营收 | 1.5% | 1.7% |
| 现金转化率经营现金流/净利润 | 2.08× | — |
| 过去12个月自由现金流最近4个季度 | $79.4M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流MCBSRGNX
| Q4 25 | $37.7M | $-52.3M | ||
| Q3 25 | $16.5M | $-56.0M | ||
| Q2 25 | $14.5M | $-49.3M | ||
| Q1 25 | $11.9M | $33.6M | ||
| Q4 24 | $63.5M | $-31.6M | ||
| Q3 24 | $-11.5M | $-40.5M | ||
| Q2 24 | $19.4M | $-45.5M | ||
| Q1 24 | $36.4M | $-55.5M |
自由现金流MCBSRGNX
| Q4 25 | $37.0M | $-52.8M | ||
| Q3 25 | $16.2M | $-56.5M | ||
| Q2 25 | $14.3M | $-49.7M | ||
| Q1 25 | $11.8M | $32.6M | ||
| Q4 24 | $62.2M | $-32.7M | ||
| Q3 24 | $-11.8M | $-40.9M | ||
| Q2 24 | $19.0M | $-46.0M | ||
| Q1 24 | $36.1M | $-56.0M |
自由现金流率MCBSRGNX
| Q4 25 | 84.7% | -174.0% | ||
| Q3 25 | 42.7% | -189.9% | ||
| Q2 25 | 37.8% | -232.8% | ||
| Q1 25 | 32.9% | 36.6% | ||
| Q4 24 | 175.8% | -154.2% | ||
| Q3 24 | -31.9% | -168.9% | ||
| Q2 24 | 52.4% | -206.2% | ||
| Q1 24 | 110.6% | -358.5% |
资本支出强度MCBSRGNX
| Q4 25 | 1.5% | 1.7% | ||
| Q3 25 | 0.7% | 1.7% | ||
| Q2 25 | 0.3% | 1.8% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | 3.6% | 5.1% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 1.0% | 2.1% | ||
| Q1 24 | 0.7% | 3.6% |
现金转化率MCBSRGNX
| Q4 25 | 2.08× | — | ||
| Q3 25 | 0.95× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.73× | 5.53× | ||
| Q4 24 | 3.91× | — | ||
| Q3 24 | -0.69× | — | ||
| Q2 24 | 1.14× | — | ||
| Q1 24 | 2.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MCBS
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
